ArticleDiscover oncology2026
Interstitial lung disease during paclitaxel trastuzumab therapy enables safe trastuzumab rechallenge: a case report and review of the literature.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe weekly Paclitaxel-Trastuzumab (wPH) regimen is frequently employed in patients with HER2-positive breast cancer who also have small tumors. Interstitial lung disease induced by paclitaxel-trastuzumab is an exceedingly uncommon side effect, referred to as drug-induced interstitial lung disease (DIILD). Identifying the specific drug responsible for ILD can be challenging when the condition arises. CASE PRESENTATION: A 58-year-old female with HER2-positive breast cancer developed interstitial pneumonitis during weekly paclitaxel plus trastuzumab therapy. Nevertheless, after paclitaxel completion and a three-month hiatus, trastuzumab was successfully reintroduced as a single agent. The patient tolerated the full subsequent year of trastuzumab monotherapy, experiencing only a transient infusion reaction without recurrence of pneumonitis.
conclusionA systematic causality assessment using the Naranjo scale, complemented by a successful single-agent rechallenge, can identify the causative agent in multi-drug DIILD and allow for the safe continuation of essential targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.